2020
Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors
Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas 2020, 144: 37-44. PMID: 33358206, PMCID: PMC7773136, DOI: 10.1016/j.maturitas.2020.10.018.Peer-Reviewed Original ResearchConceptsGynecologic cancer survivorsFemale Sexual Functioning IndexVaginal Assessment ScaleCancer survivorsLaser therapyTreatment armsSexual functionFractional COMedian total FSFI scoreMedian UDI-6 scoreRandomized sham-controlled trialUDI-6 scoresUrinary Distress InventorySerious adverse eventsSham-controlled trialProportion of patientsMedian VAS scoreTotal FSFI scoreFractional CO2 laser therapyCO2 laser therapyLaser treatmentPreliminary evidenceAdenocarcinoma histologyUrinary symptomsAdverse events
2018
Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).
Quick A, Zvinovski F, Hudson C, Hundley A, Evans C, Suresh A, Stephens J, Carpenter K, Ramaswamy B, Reinbolt R, Noonan A, VanDeusen J, Wesolowski R, Stover D, Williams N, Sardesai S, Smith K, Faubion S, Loprinzi C, Lustberg M. Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC). Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.34_suppl.202.Peer-Reviewed Original ResearchVaginal Assessment ScaleSerious adverse eventsFractional CO2 laser therapyCO2 laser therapyFemale Sexual Function IndexUrogenital Distress InventoryVaginal drynessBC survivorsBreast cancerLaser therapyStudy treatmentSingle-arm feasibility studySecondary efficacy endpointsFinal efficacy analysisSexual Function IndexER/PRFractional CO2 laser treatmentFractional CO2 laserEndocrine therapySham laserEfficacy endpointFSFI scoreAdverse eventsGenitourinary syndromePrimary efficacy